life scienc diagnost tool
strong outlook
life scienc diagnost tool initi
initi coverag six compani life scienc
diagnost tool sector favor overal life scienc tool
lst segment gener stabil end market lsd msd
growth highli correl growth high barrier entri
rel high oper effici across industri exhibit
cautiou diagnost dx segment given lower barrier
entri even perceiv signific reimburs risk lst
sector consist large-cap compani vs
growth mani compani trade year peak
multipl given sign improv across multipl end market
overal posit global econom outlook tax reform
potenti provid upsid earn expect hesit
sidelin especi lst tend outperform
period econom growth exhibit within dx focu
company-specif catalyst driver initi buy
initi neutral
predominantli valuation-driven
lst initi coverag buy
rate neutral rate expect end market
condit compar slightli better
seen biopharma comparison could remain
challeng biopharma howev could also benefit tax
reform academic/govern industri end market
shown sign stabil throughout exhibit
could balanc overal end market growth lst compani
could also benefit variou degre tax reform
could increment fx tailwind current exchang rate
dx initi coverag buy rate
encourag progress made
verigen acquisit integr believ core busi remain
stabl compani capit deploy potenti
think cusp significantli expand
address market gain expand coverag multipl
product next month
pleas read import disclosur analyst certif appear appendix
tabl content
life scienc tool diagnost invest thesi
exhibit life scienc tool diagnost sector thesi
exhibit life scienc tool stock perform januari
exhibit diagnost stock perform januari
ii life scienc tool diagnost industri snapshot
exhibit life scienc tool diagnost definit
exhibit life scienc tool diagnost top player
exhibit life scienc tool diagnost end market
life scienc tool diagnost industri driver opportun
exhibit growth driver opportun
exhibit pharma biotech spend repres one biggest growth driver lst
iv life scienc tool diagnost industri constraint potenti pitfal
life scienc tool diagnost invest thesi
exhibit life scienc tool diagnost sector thesissourc btiglif scienc tool lst what attractivelarg impact spend public privat sector global spend rise steadilyfavor secular trend increas healthcar util particularli prescript drug global due age popul rise middl class emerg marketscontinu diversif end market clinic industri food safeti materi scienc etc increas regulatori standard complex across biopharma food industri industri globallysignific headroom innov sensit faster cheaper easier use technolog typic trade premium except recessionari period watch formacroeconom condit global particularli impact europ asia-pacificspecif compani exposur differ end market geograph custom segment rich valuat compani sector trade year peak multiplesour outlook overal posit outlook lst potenti face anoth tough y/i comparison biopharma spend increment optimist end market industri academ govern europ show sign improv recent quarter exhibit overal think end market environ similar last yearth tax reform could provid ep leverag although lot move part diagnost dx pureplay companieswhat attractivepivot industri enabl precis medicinehold potenti lower cost overal healthcar servic pharmaceut pocket fast grow segment molecular diagnost infecti diseas test multiplex panel oncolog visibl medicar reimburs rate next sever year implement pama start januari watch forunpredict reimburs gain broad reimburs coverag especi new high-valu test straightforwardunattract potenti unsustain cost structur signific capit requir product develop clinic valid gain coverag decis commerci stand-alone compani profitableuncertain outlook lab industri implement pama repeal individu mandat part tax reform fierc competit among ivd manufacturersincreas cost pressur custom ivd manufacturersdifficulti differenti hype realiti mani product lack true clinic util dilemma content develop technolog platform provid face signific develop risk content develop may vulner competit follow platform provid sometim dont suffici content gain adoptionour outlook focu compani specif catalyst driver
exhibit life scienc tool stock perform januari factset cagrmarket state medic specialti state state pharmaceut major state pharmaceut gener state pharmaceut state servic industri state manag state hospital/nurs manag state electron equipment/instru state industri conglomer state internet software/servic state internet retail cap lstagil technolog intern fisher scientif lstbio-rad laboratori inc class cap lstfluidigm california perform
exhibit diagnost stock perform januari factset cagrmarket state medic specialti state state pharmaceut major state pharmaceut gener state pharmaceut state servic industri state manag state hospital/nurs manag state electron equipment/instru state industri conglomer state internet software/servic state internet retail cap dxlaboratori corpor america medicin immunotec global biosystem perform
ii life scienc tool diagnost industri snapshot
life scienc tool compani typic sell good servic research laboratori global diagnost compani typicallyselltoclinicallab provid servic themselveslif scienc tool lst compani develop sell instrument consum softwar servic research lab larg life scienc pharma biotech academ govern butalsoincreasinglytootherindustriessuchashealthcar industri food materi scienc etc vitro diagnost ivd companiesdevelopandsellinstru diagnost test consum softwar servic clinic lab market global laboratori compani provid test servic larg focus marketther overlap across three sector lst compani increasingli particip ivd market lab compani sellingkit lab etc sourc compani report market diagnost intern btiglif scienc tool market bn vitro diagnost ivd tool market bn us lab market clia clia high moder complex hospit independ labsexhibit life scienc tool diagnost -definit
sector domin player highli fragmentedth lst market grow approxim annual estim thermofish repres roughli third market theivdmarketisgrow approxim annual roch repres market follow abbott siemen lab market grow approxim annual labcorp largest compani sourc compani report market diagnost intern btignot exclud dentallif scienc tool market growthin vitro diagnost tool market growththermo fisher kgaa life scienc life scienc coulter fisher lab market growthhospit independ life scienc tool diagnost top player
lst ivd industrieshavediversifiedendmarketslst compani also sell non-lif scienc market includ industri materi scienc food test environment test chemic etc repres end market base top largest lst compani theu repres largest market lst ivd although emerg market fastest growingsourc compani report market diagnost intern btiglif scienc tool market bn ivd tool market bn exhibit life scienc tool diagnost end marketsnorth america america chemistri diagnost coagul cytolog cytometri grow base top largest lst manufactur except product mix breakdown base companiesacadem
compar compani analysi million except per share data factset btignot nr ratedexhibit life scienc tool cap agil intern fisher scientif inc tmobuy corporationwatbuy cap bio-rad laboratori inc class corporationbrkrbuy cap fluidigm bioscienc california
compar compani analysi million except per share data factset btignot nr ratedexhibit diagnost cap laboratori corpor america cap acceler diagnost inc axdxneutr scienc corporationexasneutr medicin inc mygnbuy cap caredx biochem diagnost inc gnmkbuy corplmnxbuy inc neoneutr immunotec global plcoxfdbuy ltd qtntbuy biosystem incvcytbuy btig factsetev/salesev/ebitdap/
life scienc tool diagnost industri driver opportun
btigexhibit growth driver opportunitieslstdxincreas healthcar util cost global due age popul increas chronic health condit grow middl class emerg market necessit effect prevent measur earli diseas detect precis medicinesteadi growth pharma biotech spend increas complex prescript drug develop grow proport larg molecul biolog develop growth prescript includ gener drug sale volum growth increas focu precis medicinesteadi growth spend public privat sector globallycontinu diversif end market outsid life scienc research develop manufactur industri food safeti materi scienc environment test chemic energi clinic diagnost etc emerg market particularli chinaheadroom innov
life scienc research develop favor posit backdrop global age populationwhil age popul perenni rational certain healthcar life scienc industri might attract invest think what underappreci magnitud age popul specif asia less develop region around world right lower right believ asia particularli china signific consum healthcar mani year ahead age popul coupl expans global middl class drive increasedoverallhealthcareutilizationhigh healthcar util doesnotnecessarili correl better healthcar see need effici effect healthcar spend prevent care earli detect effect therapi repres signific opportun lst dx popul age year age year develop grouppopul age year age year region un world bank btigexhibit global age populationaustraliabrazilcanadachinafrancegermanyindiaindonesiaitalyjapanmexiconetherlandss korearussiasaudi expent year expenditur per capita usd
global healthcar expenditur rise steadilyalthough absolut expenditur healthcar declin certain geograph region europ expenditur steadili risingcar expenditur growth larg outpac growth globallyu remainsthebiggestspenderon healthcar globallysourc bea btigu billionsu expendituresgrowth y/i hospit servic -physician profession servic residenti person facil continu retir medic non-dur medic public equip expenditur consumpt except invest exhibit care spend global outpac growthglob expenditur top economiesnot eu includ franc germani itali netherland spain switzerland uk includ australia brazil canada indonesia japan mexico south korea russia saudi arabia turkey eu repres averag health expenditur eu repres aggreg billion expenditur usduseuchinaindiaoth growth expenditur
ssri asthma drugsdiabet drugsarthr drugsalzheim drugscanc drugssourc evalu pharma pmc btigineffect drug class patient popul averag growth drive lst compani biopharma spend growth prescript drug salespharma spend grow lsd last sever year expect grow lsd next sever year lst compani revenu biopharmahav grow amuchfasterratehistoricallyaslst compani provid tool servic improv pharma efficiencyth increas prescript drug sale also import growth driver lst given lst compani provid qa/qc capabl pharma manufactur increasingcomplexityindrugdevelop grow proport biolog vs small molecul also representsopportunitiesforincreasedlstutilization/consumptionbybiopharma aslstenablesnecessari drug character throughoutthespectrumofdrugdiscoveri develop andmanufactur precis medicin enabl effect diagnost lst dxcompani import driver advanc precis medicin exhibit pharma biotech spend repres one biggest growth driver prescript drug sale genericsorphanprescript excl gener compound-annual-growth-rate spend growth world-wide pharma spend compound-annual-growth-rate compound-annual-growth-rate prescript over-the-counter average average product within top increas share top pharma spend bn complex drug develop continu increaseworldwid rx drug sale person medicin
nih oecd btignot fornihbudget blue bar democrat major senat hous red bar republican major senat hous purpl bar democrat major senat republican major housein gener spend global steadili increas gdpthe chart right repres spend privat public sector across industri global believ good proxi life scienc spend dont anticip meaning volatil around spend gener privat industri countri gener view invest import growth engin futur industri econom growth nih budget steadili increas low singl digit anticip trend continu long-term strong bipartisan support nih fund exhibit global gdpgross domest spend dusachinajapaneu budget nih budgetbush compound-annual-growth-rate
iv life scienc tool diagnost industri constraint potenti pitfal
exhibit life scienc tool industri potenti constraintssourc imf factset btiglst includ agil start start thermofish water meaning upsid low mid-singl digit industri growth unlikelygiven industri larg driven public privat sector spend industri growth valuat isultim constrain overal global econom growth signific barrier entri challeng associ innov new product broad-reach applic overal industri expans opportun somewhat limit view dozen mid-to large-cap changer growthasia pacificeuropenorth product -chang y/yemerg asiaeuro areaunit ntm
exhibit diagnost industri potenti pitfallssourc btigreimburs greatest challeng develop precis medicin testsfor mani emerg precis medicin test road gain broad insur coverag long uncertainw believ big part challeng payer explos new test current avail enabl signific advanc genom technolog accord concert genet uniqu genet test product market exampl averag new test ad per day order gain coverag determin diagnost test show analyt valid accuraci reliabl clinicalvalid provid actual result test claim look clinic util impact patient outcom provid necessari high qualiti evid clinic util remain biggest hurdl view signific andmeasur patient outcom chang treat physician decis make favor healthcar econom overal patient careasrequir particularli privat payer clinic util studi costli amount evid need differ payer seemarbitrari shortcut final clinic laboratori fee schedul publish purview protect access medicar act pama visibl medicar price molecular test next sever year gener proprietari test singl lab mani sequenc panel stand benefit pama implement howev uncertain implic overal lab industri includ hospit lab physician offic lab etc lab provid proprietary/esoter test willb affect ultim privat payer also uncertain pama implement may affect provid vitro diagnost ivd tool test consum lab industri believ becom increasingli import diagnost compani equip tangibl cost efficaci and/or healthcar econom strategi competit ivd develop especi target molecular diagnost fastest grow segment believ market get somewhat crowd new emerg technolog evolutionari revolutionari technolog platform chase limit numberofappl could increas price pressur industri
compani report btigexhibit life scienc tool end market color first month oct fye danaherthermo tough comp good demand sciex particular strength china biopharma drove msd growth pall life scienc hsd strong bioproduct bioscienc sciex msd led pharma doubl digit growth singl use technolog msd strength bioscienc chromatographi ms research safeti market channel sustain momentum pharma test sciex pall doubl digit order growth biopharma msd strength chromatographi ms bioscienc research safeti market channel strength larg molecul biomed research declin tough expect hesit point specif project lsd similar last year sale sciex academ demand stabl across geographi lsd improv asian european market relat environment medic research applic start see sign increas activ us government fund lsd growth quarter declin msd strong perform europ china broad-bas perform across major quarter y/i declin chemic compani begin increas purchas energi explor refin busi remain challeng food test driven china enviro forens pall industri slightli environment appli solut compani averag growth strong appli market good growth research safeti market channel industri custom industri materi food environment fine chemic market grew stronger expect chemic energi growth materi mine custom also start reinvest food difficut comp environment forens sciex msd led food test environment appli solut compani averag good demand research safeti market channel industri custom environment food safeti remain strong chemic energi food grew environment forens environment appli solut msd continu benefit increas global demand particular strength across analyt instrument busi asia-pacif strength materi chemic energi food environment forens revenu y/i report revenu core revenu report revenu core revenu report revenu core revenu lsd good growth transplant biotechacadem governmentindustri applieddiagnost clinic
compani report btigexhibit life scienc tool end market color first month continu agil oct fye danaherthermo msd develop market lsd north america lsd declin america us due small molecul pharma segment vs strong doubl digit growth prior year slower budgetari solid result us compani averag america us macroeconom government polici uncertainti appear affect gener busi msd solid result us lsd sale flat america us sale despit natur disast macro government polici uncertainti flat msd strength pharma robust demand industri off-set weak government academ western eu doubl digit eastern eu grew off-set solid result develop market lsd led pharma government doubl digit growth msd broad-bas growth hsd low doubl digit growth china japan flat continu strength china india ldd china high teen asia doubl digit growth china growth pharma industri doubl digit growth india japan declin difficult grew china grew hsd solid result japan china hsd hsd china mid-teen asia china grew faster overal asia doubl digit growth india continu strong china japan flat solid result japan china doubl digit ldd china high teen asia china strength across core market japan strong government academ steadi pharma growth grew faster overal asia good servic tax impact india hsd growth china asia ex china/japan lsdu americaseuropeasia pacif
factset btiginclud compani market capit billion and/or million revenuesexhibit diagnost compani ebitda profil cap mm revenu ebitda mm
btig cover compani mention report
appendix analyst certif import disclosur
